Evidence map›Paper›PMID 34307485›Full record

ArticleSkin appendage disorders2021

Successful Treatment of Coexistent Acne Fulminans and Severe Hidradenitis Suppurativa with Adalimumab.

George Kontochristopoulos, Efthymia Agiasofitou, Eftychia Platsidaki, Anastasia Kapsiocha, Stamatios Gregoriou, Dimitrios Rigopoulos

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Skin appendage disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

George KontochristopoulosDepartment of Dermatology and Venereology, Andreas Sygros Hospital, Athens, Greece.
Efthymia AgiasofitouDepartment of Dermatology and Venereology, Andreas Sygros Hospital, Athens, Greece.
Eftychia PlatsidakiDepartment of Dermatology and Venereology, Andreas Sygros Hospital, Athens, Greece.
Anastasia KapsiochaDepartment of Dermatology and Venereology, Andreas Sygros Hospital, Athens, Greece.
Stamatios GregoriouNational and Kapodistrian University of Athens, Faculty of Medicine, 1st department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece.
Dimitrios RigopoulosNational and Kapodistrian University of Athens, Faculty of Medicine, 1st department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece.
Andreas Sygros Hospital · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coexistence of hidradenitis suppurativa (HS) and acne fulminans (AF) has only recently been reported in the literature. We present a case of a 17-year-old man who presented with a 2 years history of severe acne and HS. He was initially started on oral clindamycin and rifampicin for 3 months with no clinical improvement. Acne lesions became worse with the presence of nodules and necrotic ulcers, while weight loss, low-grade fever, back and knee pain, and psychological distress were noted. We prescribed adalimumab in its standard dosing regimen. Remission of AF was achieved in 3 months, whereas adalimumab has not been as effective in treating the HS lesions. Its dosage was increased to 80 mg weekly and more than 80% clinical improvement of HS lesions was obtained in 2 months. The patient maintained on this dosage till this day and efficacy is sustained. TNF-α inhibitors are considered an effective option in the treatment of HS, while it has been also suggested as a treatment option in AF. Our patient was successfully treated with adalimumab. Since the coexistence of HS and AF has a devastating emotional effect on the patient, there is an urgent need to implement therapeutic approaches.

Indexed as

Acne fulminansAdalimumabHidradenitis suppurativa

Identifiers

PMID34307485
PMCPMC8280433
OpenAlexW3145502953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.